Design Therapeutics, Inc.

NASDAQ:DSGN

Biotechnology

Healthcare
$9.47 +1.59%

+$0.19 today

Market cap
$606.42M
Beta
1.66
P/E (TTM)
-10.7
EPS (TTM)
-$1.13
52W Low $3.33High $17.25

Volume 0.32M

Average 0.74M

Balance Sheet

Inspect the capital base behind the business.

Assets

$226.20M

FY 2025 · Annual

-10.3% YoY

Liabilities

$13.70M

FY 2025 · Annual

+37.1% YoY

Equity

$212.50M

FY 2025 · Annual

-12.2% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents298.57M26.5M21.2M22.56M16.86M
Short-term Investments85.5M303.89M260.6M222.91M202.99M
Net Receivables110K1.12M1.43M1.26M1.68M
Inventory00000
Other Current Assets00000
Total Current Assets385.44M335.12M284.58M248.04M223.78M
Property, Plant & Equipment (Net)5.12M5.56M4.63M3.63M2.42M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0459K430K427K0
Total Non-current Assets5.12M6.02M5.06M4.05M2.42M
Total Assets390.56M341.14M289.64M252.09M226.2M
Account Payables1.62M3.03M1.94M2.19M2.31M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.15M3.54M4.03M3.58M4.63M
Total Current Liabilities5.28M10.78M9.62M8.46M13.06M
Long-term Debt0000645K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities3.14M3.05M2.33M1.53M645K
Total Liabilities8.43M13.83M11.96M10M13.7M
Common Stock6K6K6K6K6K
Retained Earnings(47.46M)(110.76M)(177.63M)(227.21M)(297.01M)
Accumulated OCI(244K)(3.36M)62K475K403K
Other Stockholders Equity00000
Minority Interest00000
Total Equity382.13M327.31M277.69M242.1M212.5M
Total Debt3.63M3.69M3.05M2.33M1.54M
Net Debt(294.94M)(22.81M)(18.15M)(20.23M)(15.32M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$12.8M
Short-term Investments$210.1M
Receivables$1.8M
Other Current$2.4M
Total Current Assets$227.0M
PP&E (Net)$3.4M
Total Non-current Assets$3.4M
Total Assets$230.4M

Analysis

Selected assets total $230.4M for Latest. The largest visible component is Short-term Investments at $210.1M, about 91.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
EFFECTEFFECT filingNov 12, 2026
424B5424B5 filingNov 4, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 4, 2026
S-3S-3 filingNov 4, 2026

How much cash does DSGN have?

Design Therapeutics, Inc. (DSGN) reported $16.86M in cash and equivalents in fiscal 2025.

How much debt does DSGN carry?

Design Therapeutics, Inc. (DSGN) reported $1.53M of total debt, with net debt of -$15.32M.